Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
29 hedge funds and large institutions have $3.71M invested in Acorda Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 6 closing their positions.
11% more call options, than puts
Call options by funds: $21K | Put options by funds: $19K
9% less capital invested
Capital invested by funds: $4.09M → $3.71M (-$382K)
15% less funds holding
Funds holding: 34 → 29 (-5)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$163K |
| 2 |
Renaissance Technologies
New York
|
+$13.6K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$10.8K |
| 4 |
HF
HRT Financial
New York
|
+$10.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DKCM
Davidson Kempner Capital Management
New York
|
-$492K |
| 2 |
SC
Saltoro Capital
Dallas,
Texas
|
-$47.7K |
| 3 |
Prudential Financial
Newark,
New Jersey
|
-$24.1K |
| 4 |
UAS
United Asset Strategies
Garden City,
New York
|
-$20.8K |
| 5 |
Millennium Management
New York
|
-$19.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Russell Investments Group
London,
United Kingdom
| $3.52K | – | – | – |
|
27
First Manhattan
New York
| $29 | – | – | – |
|
|
28
Prudential Financial
Newark,
New Jersey
| – | -$24.1K | -1,570 | Closed |
|
|
UAS
29
United Asset Strategies
Garden City,
New York
| – | -$20.8K | -1,355 | Closed |
|
30
Verition Fund Management
Greenwich,
Connecticut
| – | -$10.5K | -682 | Closed |
|
31
Citigroup
New York
| – | -$272 | -18 | Closed |
|
|
IAS
32
IMA Advisory Services
Denver,
Colorado
| – | -$13 | -1 | Closed |
|
|
JFA
33
JNBA Financial Advisors
Bloomington,
Minnesota
| – | -$1 | – | – |
|
ACOR Hedge Fund Activity: Q1 2023 in Review
29 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2023, worth a combined $3.71M — down 9.3% from $4.09M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ACOR and 2 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Susquehanna International Group, adding an estimated $163K. The largest seller was Davidson Kempner Capital Management, cutting an estimated $492K.
- 29 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2023, down from 34 in Q4 2022.
- Funds reported $3.71M of Acorda Therapeutics stock for Q1 2023, down 9.3% quarter-over-quarter.
- 2 funds opened new Acorda Therapeutics positions in Q1 2023 and 6 closed out, a net change of -4 holders.
- The largest Acorda Therapeutics buyer in Q1 2023 was Susquehanna International Group, an estimated $163K added.
- The largest Acorda Therapeutics seller in Q1 2023 was Davidson Kempner Capital Management, an estimated $492K sold.
Based on aggregated 13F filings for Q1 2023.